DAMORA THERAPEUTICS, INC. Proceeds from Sale and Maturity of Marketable Securities
DAMORA THERAPEUTICS, INC. (DMRA) reported Proceeds from Sale and Maturity of Marketable Securities of $11.65 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-03-19
- DAMORA THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2024-06-30 was $6.00M, a 51.35% decline year-over-year.
- DAMORA THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2024-03-31 was $5.65M, a 60.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2024 was $11.65M, a 75.82% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $48.18M, a 16.12% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $57.45M, a 57.89% increase from fiscal 2021.
- DAMORA THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2021 was $36.38M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $6.00M derived: sum of 3 quarters · filed 2026-03-19 | $11.65M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.00M derived: sum of 2 quarters · filed 2025-11-06 | $11.65M 10-Q · filed 2025-11-06 | $21.15M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $11.65M 10-Q · filed 2025-08-05 | $21.15M derived: sum of 3 quarters · filed 2025-08-05 | $33.38M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $5.65M 10-Q · filed 2025-05-08 | $15.15M derived: sum of 2 quarters · filed 2025-05-08 | $27.38M derived: sum of 3 quarters · filed 2025-05-08 | $39.71M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $21.73M derived: sum of 2 quarters · filed 2025-03-19 | $34.06M derived: sum of 3 quarters · filed 2025-03-19 | $48.18M 10-K · filed 2025-03-19 |
| 2023-09-30 | $12.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $24.56M derived: sum of 2 quarters · filed 2024-11-01 | $38.69M 10-Q · filed 2024-11-01 | $57.27M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $12.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $26.46M 10-Q · filed 2024-08-12 | $45.04M derived: sum of 3 quarters · filed 2024-08-12 | $53.49M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $14.13M 10-Q · filed 2024-04-29 | $32.70M derived: sum of 2 quarters · filed 2024-04-29 | $41.16M derived: sum of 3 quarters · filed 2024-04-29 | $55.35M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $18.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $27.03M derived: sum of 2 quarters · filed 2024-03-08 | $41.22M derived: sum of 3 quarters · filed 2024-03-08 | $57.45M 10-K · filed 2024-03-08 |
| 2022-09-30 | $8.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $22.64M derived: sum of 2 quarters · filed 2023-11-06 | $38.87M 10-Q · filed 2023-11-06 | $53.27M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $14.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $30.41M 10-Q · filed 2023-07-31 | $44.82M derived: sum of 3 quarters · filed 2023-07-31 | $55.08M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $16.22M 10-Q · filed 2023-04-28 | $30.63M derived: sum of 2 quarters · filed 2023-04-28 | $40.88M derived: sum of 3 quarters · filed 2023-04-28 | |
| 2021-12-31 | $14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $24.66M derived: sum of 2 quarters · filed 2023-03-09 | $36.38M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $10.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $21.98M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $11.72M 10-Q · filed 2022-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |